Contributions
Abstract: EP1547
Type: ePoster
Abstract Category: Therapy - disease modifying - Others
Background: Multiple sclerosis (MS) is a chronic neurodegenerative disease associated with functional and cognitive deficits. There are numerous disease-modifying therapies (DMTs) available for the treatment of MS, each with efficacy profiles within a similar range and acceptable safety and tolerability profiles. Therefore, real-world evidence on patient-reported treatment experience is becoming increasingly important in helping differentiate and define the value aspects of MS therapies to patients, clinicians, and payers.
Objective: To investigate treatment burden, preference, and satisfaction associated with route of administration of DMTs in patients with relapsing-remitting MS (RRMS).
Methods: Data on treatment experience, preference, and satisfaction were collected through a self-administrated online survey from patients with RRMS in the US and five major countries in the European Union (France, Germany, Italy, Spain, and the UK; EU5). Treatment satisfaction was measured using the Treatment Satisfaction Questionnaire for Medication (TSQM, version 1.4), a validated patient-reported outcome measure comprising 4 domains: Effectiveness, Side Effects, Convenience, and Global Satisfaction. Patients receiving oral (teriflunomide, fingolimod, dimethyl fumarate), subcutaneous injectable (glatiramer acetate, pegylated interferon beta-1a, interferon beta-1a, interferon beta-1b), or intramuscular injectable (interferon beta-1a) DMTs were included in the study. Descriptive and bivariate analyses were performed on the survey outcomes. Results were further stratified by the number of routes of administration patients experienced due to switching, in treating their MS.
Results: A total of 744 patients aged 21-65 years with RRMS completed the survey; 435 patients from the US and 309 from the EU5. The proportion of patients receiving an oral DMT as a first, second, third, or fourth line of therapy was 20.9%, 54.4%, 60.8%, and 78.4%, respectively. Patient preference for oral DMTs increased with treatment switches (P< 0.001). In the TSQM domains of Convenience and Side Effects, patient satisfaction was significantly higher (P< 0.001) for patients currently using oral DMTs compared with patients using injectable DMTs.
Conclusions: As patients" experience with DMTs grows, there is an increase in patient preference toward oral DMTs over injectable DMTs. Higher treatment satisfaction regarding side effects and convenience for orals may account for this.
Disclosure: Study supported by Sanofi Genzyme.
JM: Employee of Sanofi Genzyme.
SH: Employee of Sanofi Genzyme.
FC: Employee of Sanofi Genzyme;
FT: Contractor for Sanofi Genzyme.
Abstract: EP1547
Type: ePoster
Abstract Category: Therapy - disease modifying - Others
Background: Multiple sclerosis (MS) is a chronic neurodegenerative disease associated with functional and cognitive deficits. There are numerous disease-modifying therapies (DMTs) available for the treatment of MS, each with efficacy profiles within a similar range and acceptable safety and tolerability profiles. Therefore, real-world evidence on patient-reported treatment experience is becoming increasingly important in helping differentiate and define the value aspects of MS therapies to patients, clinicians, and payers.
Objective: To investigate treatment burden, preference, and satisfaction associated with route of administration of DMTs in patients with relapsing-remitting MS (RRMS).
Methods: Data on treatment experience, preference, and satisfaction were collected through a self-administrated online survey from patients with RRMS in the US and five major countries in the European Union (France, Germany, Italy, Spain, and the UK; EU5). Treatment satisfaction was measured using the Treatment Satisfaction Questionnaire for Medication (TSQM, version 1.4), a validated patient-reported outcome measure comprising 4 domains: Effectiveness, Side Effects, Convenience, and Global Satisfaction. Patients receiving oral (teriflunomide, fingolimod, dimethyl fumarate), subcutaneous injectable (glatiramer acetate, pegylated interferon beta-1a, interferon beta-1a, interferon beta-1b), or intramuscular injectable (interferon beta-1a) DMTs were included in the study. Descriptive and bivariate analyses were performed on the survey outcomes. Results were further stratified by the number of routes of administration patients experienced due to switching, in treating their MS.
Results: A total of 744 patients aged 21-65 years with RRMS completed the survey; 435 patients from the US and 309 from the EU5. The proportion of patients receiving an oral DMT as a first, second, third, or fourth line of therapy was 20.9%, 54.4%, 60.8%, and 78.4%, respectively. Patient preference for oral DMTs increased with treatment switches (P< 0.001). In the TSQM domains of Convenience and Side Effects, patient satisfaction was significantly higher (P< 0.001) for patients currently using oral DMTs compared with patients using injectable DMTs.
Conclusions: As patients" experience with DMTs grows, there is an increase in patient preference toward oral DMTs over injectable DMTs. Higher treatment satisfaction regarding side effects and convenience for orals may account for this.
Disclosure: Study supported by Sanofi Genzyme.
JM: Employee of Sanofi Genzyme.
SH: Employee of Sanofi Genzyme.
FC: Employee of Sanofi Genzyme;
FT: Contractor for Sanofi Genzyme.